StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study

Overview

This active vs active comparative trial will evaluate the safety and efficacy of incremental doses of atropine in combination with pseudoephedrine 120 mg/chlorpheniramine 8 mg in adult patients with a history of seasonal allergic rhinitis. Hypotheses are defined by total nasal symptom scores (TNSS) recorded by subjects in diaries where efficacy will be established by statistical significance where p < 0.05.

Full Title of Study: “A Phase 2, Double-Blind, Parallel-Group, Dose-Ranging Study Evaluating Safety/ Efficacy Atropine Doses With Pseudoephedrine and Chlorpheniramine in SAR Patients 12 Years of Age and Older”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: May 2014

Detailed Description

Actives in each of the five study arms:

Pseudoephedrine 120 mg/Chlorpheniramine 8 mg/Atropine 0.36 mg Pseudoephedrine 120 mg/Chlorpheniramine 8 mg/Atropine 0.24 mg Pseudoephedrine 120 mg/Chlorpheniramine 8 mg/Atropine 0.12 mg Pseudoephedrine 120 mg/Chlorpheniramine 8 mg Atropine 0.24 mg

Interventions

  • Drug: PSE 120 mg, CM 8 mg, Atr 0.36 mg
    • Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.36 mg white, scored, tablets with “M27″ on scored side and plain on the other side
  • Drug: PSE 120 mg, CM 8 mg, Atr 0.24 mg
    • Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg white, scored, tablets with “M27″ on scored side and plain on the other side
  • Drug: PSE 120 mg, CM 8 mg, Atr 0.12 mg
    • Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 mg white, scored, tablets with “M27″ on scored side and plain on the other side
  • Drug: PSE 120 mg, CM 8 mg
    • Pseudoephedrine 120 mg, chlorpheniramine 8 mg tablets dosed BID
  • Drug: Atropine 0.24 mg
    • Atropine sulfate 0.24 mg white, scored, tablets with “M27″ on scored side and plain on the other side

Arms, Groups and Cohorts

  • Experimental: PSE 120 mg, CM 8 mg, Atr 0.36 mg
    • Pseudoephedrine 120 mg,chlorpheniramine 8 mg, atropine 0.36 mg tablet dosed BID for 7.5 days
  • Experimental: PSE 120 mg, CM 8 mg, Atr 0.24 mg
    • Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg tablets dosed BID for 7.5 days
  • Experimental: PSE 120 mg, CM 8 mg, Atr 0.12 mg
    • Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 dosed BID for 7.5 days
  • Active Comparator: PSE 120 mg, CM 8 mg
    • Pseudoephedrine 120 mg, chlorpheniramine 8 mg white, scored, tablets with “M27″ on scored side and plain on the other side
  • Experimental: Atropine 0.24 mg
    • Atropine 0.24 mg tablets dosed BID for 7.5 days

Clinical Trial Outcome Measures

Primary Measures

  • Dose-ranging data for atropin
    • Time Frame: 7.5 days
    • To provide dose-ranging data for atropine and select a dose of Atropine for Phase 3 clinical development using Total Nasal Symptom Score (TNSS) as the primary endpoint plus recording of adverse events

Secondary Measures

  • Establish effect size for determining power and TNSS efficacy endpoint
    • Time Frame: 7.5 days
    • To establish an effect size of a Pseudoephedrine 120 mg/Chlorpheniramine 8 mg/Atropine combination versus Pseudoephedrine 120 mg/Chlorpheniramine 8 mg to statistically power the pivotal phase of the study using TNSS as the primary endpoint

Participating in This Clinical Trial

Inclusion Criteria

1. Male and females of any ethnic group between 12 and 60 years of age.

2. History of moderate to severe SAR for at least two years; defined as having a score of 2 or more on a 0-3 point scale

3. Documentation of sensitivity will be obtained from medical records or positive skin testing or in vitro specific IgE test.

4. Have a TNSS score of 6 with at least an average of 2.0 in the rhinorrhea sub-score during the placebo-run in phase.

5. Is a non-pregnant, non-lactating female who is postmenopausal, naturally or surgically sterile, or who agree to use effective contraceptive methods throughout the course of the study.

6. If female of childbearing potential, must agree to use listed acceptable birth control methods…

7. If female of childbearing potential, has a negative urine human chorionic gonadotropin (hCG) pregnancy test at screening

8. Is able to swallow whole tablets of orally administered medication

9. Is able to understand and provide signed informed consent

Exclusion Criteria

1. Has asthma requiring corticosteroid treatment

2. Is currently undergoing chronic or intermittent use of inhaled, oral, intramuscular, intravenous, and/or potent or super potent topical corticosteroids

3. Has taken any of the following medications in the indicated time period prior to study enrolment:

  • Intranasal, opthalmic, or systemic corticosteroids (1 month)
  • Intranasal cromolyn (2 weeks)
  • Intranasal or systemic decongestants (3 days)
  • Intranasal or systemic antihistamines (7 days) or leukotriene inhibitors (7 days)

4. Documented evidence of acute or significant chronic sinusitis, as determined by the individual investigator

5. Has a history of allergic reaction to or known sensitivity to the active or inactive ingredients in the investigational products used in this study

6. Chronic use of concomitant medications (e.g., tricyclic antidepressants) that would affect assessment of the effectiveness of the study medication

7. Rhinitis medicamentosa

8. A history of glaucoma

9. Has known or suspected pregnancy, planned pregnancy, or lactation (for female patients)

10. Is currently receiving immunotherapy, unless at stable maintenance dose for at least 1 month.

11. Presence of a medical condition that might interfere with treatment evaluation or require a change in therapy.

12. Plans to travel outside the study area for a substantial portion of the study period

13. Has a history in the last 2 years or current evidence of abuse of illicit drugs, prescription medications, or alcohol that, in the opinion of the Investigator, would interfere with adherence to study requirements.

14. Has exposure to any investigational agent within 30 days prior to study entry.

15. Has clinically significant mental illness (to be determined by the Investigator)

16. Has a condition the Investigator believes would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results or put the patient at undue risk

Gender Eligibility: All

Minimum Age: 12 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Magna Pharmaceuticals, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Stephen J Pollard, MD, Principal Investigator, Family Allergy and Asthma

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.